HER2 Key Differences and Current Approaches to Biomarker Testing
Panelist discusses how HER2 testing evaluates protein overexpression, gene amplification, and mutations. Although breast and gastric cancers typically show overexpression/amplification, other tumors more commonly harbor mutations.
EP: 1.Introduction to HER2-Directed Tumor-Agnostic Approaches
EP: 2.HER2 Key Differences and Current Approaches to Biomarker Testing
EP: 3.Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
EP: 4.Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
EP: 5.Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
EP: 6.Future of HER2-Directed Tumor-Agnostic Therapies
Video content above is prompted by the following:
- What are the key differences between HER2 overexpression, amplification, and mutations across tumor types? How do these differences affect treatment selection?
- What is your current approach to biomarker testing for HER2 alterations across different tumor types?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
